MIRA Pharmaceuticals (MIRA) Competitors $1.21 -0.03 (-2.50%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MIRA vs. JMAC, ZURA, OCX, IZTC, PYXS, GALT, IMUX, SNTI, CLLS, and FBRXShould you be buying MIRA Pharmaceuticals stock or one of its competitors? The main competitors of MIRA Pharmaceuticals include Maxpro Capital Acquisition (JMAC), Zura Bio (ZURA), OncoCyte (OCX), Invizyne Technologies (IZTC), Pyxis Oncology (PYXS), Galectin Therapeutics (GALT), Immunic (IMUX), Senti Biosciences (SNTI), Cellectis (CLLS), and Forte Biosciences (FBRX). These companies are all part of the "pharmaceutical products" industry. MIRA Pharmaceuticals vs. Its Competitors Maxpro Capital Acquisition Zura Bio OncoCyte Invizyne Technologies Pyxis Oncology Galectin Therapeutics Immunic Senti Biosciences Cellectis Forte Biosciences MIRA Pharmaceuticals (NASDAQ:MIRA) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, analyst recommendations, risk, profitability, community ranking, institutional ownership and earnings. Do insiders and institutionals hold more shares of MIRA or JMAC? 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer MIRA or JMAC? In the previous week, MIRA Pharmaceuticals had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for MIRA Pharmaceuticals and 0 mentions for Maxpro Capital Acquisition. MIRA Pharmaceuticals' average media sentiment score of 1.44 beat Maxpro Capital Acquisition's score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment MIRA Pharmaceuticals Positive Maxpro Capital Acquisition Neutral Which has more volatility & risk, MIRA or JMAC? MIRA Pharmaceuticals has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, indicating that its share price is 99% less volatile than the S&P 500. Does the MarketBeat Community prefer MIRA or JMAC? MIRA Pharmaceuticals received 3 more outperform votes than Maxpro Capital Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformMIRA PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Maxpro Capital AcquisitionN/AN/A Is MIRA or JMAC more profitable? Maxpro Capital Acquisition's return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -337.44% -280.58% Maxpro Capital Acquisition N/A N/A N/A Which has better earnings and valuation, MIRA or JMAC? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$11.98M-$0.51-2.37Maxpro Capital AcquisitionN/AN/AN/AN/AN/A Do analysts rate MIRA or JMAC? MIRA Pharmaceuticals presently has a consensus target price of $14.00, indicating a potential upside of 1,057.02%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe MIRA Pharmaceuticals is more favorable than Maxpro Capital Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryMIRA Pharmaceuticals beats Maxpro Capital Acquisition on 8 of the 12 factors compared between the two stocks. Get MIRA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MIRA vs. The Competition Export to ExcelMetricMIRA PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.47M$6.87B$5.57B$8.50BDividend YieldN/A2.52%5.28%4.16%P/E Ratio-2.168.4326.6319.64Price / SalesN/A262.52407.99152.17Price / CashN/A65.8538.2534.64Price / Book4.036.536.964.60Net Income-$11.98M$143.25M$3.23B$248.06M7 Day Performance-13.57%-0.06%-1.13%-0.94%1 Month Performance-9.02%11.77%8.59%3.52%1 Year Performance63.96%3.66%33.63%14.02% MIRA Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MIRAMIRA Pharmaceuticals3.3237 of 5 stars$1.21-2.4%$14.00+1,057.0%+70.4%$20.47MN/A-2.162Positive NewsShort Interest ↓JMACMaxpro Capital AcquisitionN/A$6.50flatN/A+3,215.2%$87.28MN/A0.002,021ZURAZura Bio2.6395 of 5 stars$1.25-0.8%$14.33+1,046.7%-67.8%$85.47MN/A-1.793Analyst RevisionGap UpOCXOncoCyte2.8001 of 5 stars$2.78-6.4%$6.06+118.1%-1.1%$84.94M$3.84M-0.79120Positive NewsGap UpIZTCInvizyne TechnologiesN/A$13.44-1.8%N/AN/A$84.00MN/A0.00N/APositive NewsGap DownPYXSPyxis Oncology2.2391 of 5 stars$1.35flat$9.00+566.7%-69.6%$83.63M$16.15M-1.3160Positive NewsGALTGalectin Therapeutics1.1709 of 5 stars$1.32flat$11.00+733.3%-48.5%$83.55MN/A-1.819IMUXImmunic3.1776 of 5 stars$0.87+10.0%$11.60+1,237.5%-34.6%$83.10MN/A-0.7170Short Interest ↑High Trading VolumeSNTISenti Biosciences2.3336 of 5 stars$3.12-18.8%$8.50+172.4%-1.2%$81.37M$2.56M-0.204Analyst ForecastGap DownCLLSCellectis3.6025 of 5 stars$1.43+1.1%$7.00+391.2%-43.6%$79.21M$47.63M-1.10290Positive NewsFBRXForte Biosciences3.033 of 5 stars$11.95+5.6%$61.00+410.5%+54,261.5%$78.67MN/A-0.735Options VolumeGap Up Related Companies and Tools Related Companies Maxpro Capital Acquisition Competitors Zura Bio Competitors OncoCyte Competitors Invizyne Technologies Competitors Pyxis Oncology Competitors Galectin Therapeutics Competitors Immunic Competitors Senti Biosciences Competitors Cellectis Competitors Forte Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MIRA) was last updated on 6/14/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGet in stocks now - and get out on this dateGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[First Look] Get in before potential 10X AI announcementsGo for 10X gains from the next big AI announcement — starting as soon as 7 days from now Former floor trade...Masters in Trading | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MIRA Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MIRA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
